225 Actinium PSMA 617 - Endocyte

Drug Profile

225 Actinium PSMA 617 - Endocyte

Alternative Names: 225 Actinium PSMA 617; 225Ac PSMA 617

Latest Information Update: 02 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Endocyte
  • Developer Endocyte; Memorial Sloan-Kettering Cancer Center
  • Class Antineoplastics; Radiopharmaceuticals
  • Mechanism of Action Ionising radiation emitters
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostate cancer

Most Recent Events

  • 02 Nov 2017 Preclinical trials in Prostate cancer (Metastatic disease) in USA (Parenteral)
  • 02 Nov 2017 Endocyte, in collaboration with the Memorial Sloan Kettering Cancer Center plans a phase I trial of 225Ac-PSMA-617, in 1H 2018, for the treatment of patients with metastatic castration-resistant prostate cancer.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top